Workflow
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
VYGRVoyager Therapeutics(VYGR) GlobeNewswire News Room·2025-03-11 20:01

Core Insights - Voyager Therapeutics has made significant advancements in its anti-tau programs targeting Alzheimer's disease, with VY7523 in clinical trials and VY1706 in IND-enabling studies [2] - The company generated approximately 80millioninnon−dilutivefundingin2024,whichisexpectedtosupportoperationsthroughmid−2027[2]−CollaborationrevenuesdecreasedsignificantlyinQ42024andforthefullyearcomparedto2023,primarilyduetoreducedrevenuefromNeurocrineandNovartisagreements[5][8]FinancialResults−CollaborationrevenueforQ42024was80 million in non-dilutive funding in 2024, which is expected to support operations through mid-2027 [2] - Collaboration revenues decreased significantly in Q4 2024 and for the full year compared to 2023, primarily due to reduced revenue from Neurocrine and Novartis agreements [5][8] Financial Results - Collaboration revenue for Q4 2024 was 6.3 million, down from 90.1millioninQ42023;totalcollaborationrevenuefor2024was90.1 million in Q4 2023; total collaboration revenue for 2024 was 80.0 million compared to 250.0millionin2023[5][18]−NetlossforQ42024was250.0 million in 2023 [5][18] - Net loss for Q4 2024 was 34.5 million, compared to a net income of 56.4millioninQ42023;thefullyearnetlosswas56.4 million in Q4 2023; the full year net loss was 65.0 million versus a net income of 132.3millionin2023[14][19]−Researchanddevelopmentexpensesincreasedto132.3 million in 2023 [14][19] - Research and development expenses increased to 35.6 million in Q4 2024 from 25.8 million in Q4 2023, with total R&D expenses for 2024 at 127.4 million compared to 92.2millionin2023[14][19]UpcomingMilestones−VY1706isexpectedtofileforINDin2026,withadditionaldatatobepresentedattheADPDconferenceinApril2025[6][7]−InitialtauPETimagingdataforVY7523isanticipatedinthesecondhalfof2026[6]−INDfilingsforpartneredgenetherapiesrelatedtoGBA1Parkinson′sandFriedreich′sataxiaareexpectedin2025[7]CashPosition−AsofDecember31,2024,Voyagerhadcash,cashequivalents,andmarketablesecuritiestotaling92.2 million in 2023 [14][19] Upcoming Milestones - VY1706 is expected to file for IND in 2026, with additional data to be presented at the ADPD conference in April 2025 [6][7] - Initial tau PET imaging data for VY7523 is anticipated in the second half of 2026 [6] - IND filings for partnered gene therapies related to GBA1 Parkinson's and Friedreich's ataxia are expected in 2025 [7] Cash Position - As of December 31, 2024, Voyager had cash, cash equivalents, and marketable securities totaling 332.4 million, an increase from $230.9 million in 2023 [14][19] - The company's cash runway is projected to extend into mid-2027, not including potential milestone payments from existing partnerships [9][14]